ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

• ChemoCentryx (NASDAQ:CCXI) down 5% after hours on topline data from Phase 2 study, ACCOLADE, evaluating avacopan for the treatment of C3 glomerulopathy (kidneys malfunction leading to excess levels of protein in urine).
• The trial showed the change from baseline to week 26 in C3 glomerulopathy (C3G) activity score (primary endpoint) was not statistically different between two treatment groups, while the the index measuring progression of fibrosis demonstrated significant benefit for avacopan versus placebo.
• Placebo group worsened by 38% on average in the C3G activity score while the avacopan group improved by 2% on average. C3G index for disease chronicity was 58% in avacopan versus 32% in placebo.
• According to the data, patients who received avacopan experienced significant benefits in terms of kidney function and other parameters compared to those who received placebo
• On the safety front, avacopan was safe and well-tolerated.
• Data from the open label and follow up period will be analyzed and presented at a future time.
• Small molecule avacopan inhibits the complement C5a receptor, which plays a key role in the inflammatory process.